Search News
| 23.86 Delayed Data As of Sep 24 |  -0.50 / -2.05%Today’s Change | 10.85 Today|||52-Week Range 25.96 | +25.91% Year-to-Date |
| 5 Asian Stocks Gurus Agree On Sep 24 / GuruFocus News - Paid Partner Content | Does Ajovy's Approval Make Teva a Pain-Free Stock to Buy? Sep 18 / MotleyFool.com - Paid Partner Content |
| Lilly's Migraine Drug Emgality Wins Positive CHMP Opinion Sep 24 / Zacks.com - Paid Partner Content | New Marijuana Stocks? & Earnings from ORCL and FDX | Free Lunch Sep 17 / Zacks.com - Paid Partner Content |
| AbbVie/Roche's Leukemia Drugs Combo Gets CHMP Backing in EU Sep 24 / Zacks.com - Paid Partner Content | Teva's (TEVA) Migraine Drug Ajovy Receives FDA Approval Sep 17 / Zacks.com - Paid Partner Content |
| AstraZeneca's Fasenra Long-Term Asthma Study Data Positive Sep 19 / Zacks.com - Paid Partner Content | Allergan Frown Lines Study Passes Test on Higher Botox Dose Sep 17 / Zacks.com - Paid Partner Content |
| Regeneron Gains on Eylea, Dupixent and Pipeline Progress Sep 18 / Zacks.com - Paid Partner Content | Regeneron-Sanofi Report Data on Dupixent in Atopic Dermatitis Sep 17 / Zacks.com - Paid Partner Content |
| Previous close | 24.36 |
| Today’s open | 24.24 |
| Day’s range | 23.62 - 24.41 |
| Volume | 9,955,633 |
| Average volume (3 months) | 11,192,279 |
| Market cap | $24.8B |
| Earnings growth (last year) | -23,426.50% |
| Earnings growth (this year) | -30.34% |
| Earnings growth (next 5 years) | 0.00% |
| Revenue growth (last year) | +2.60% |
| P/E ratio | NM |
| Price/Sales | 0.85 |
| Price/Book | 1.80 |
| Next reporting date | November 1, 2018 |
| EPS forecast (this quarter) | $0.55 |
| Annual revenue (last year) | $22.5B |
| Annual profit (last year) | -$16.4B |
| Net profit margin | -72.66% |
Sector Health Technology |
Industry Pharmaceuticals: Generic |
President, Chief Executive Officer & Director Kåre Schultz |
Executive Vice President- Global Operations Carlo de Notaristefani |
Corporate headquarters Petach Tikva, Hamerkaz |
